Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis
Michael P Pender, Peter A Csurhes, Corey Smith, Leone Beagley, Kaye D Hooper, Meenakshi Raj, Alan Coulthard, Scott R Burrows, Rajiv Khanna, Michael P Pender, Peter A Csurhes, Corey Smith, Leone Beagley, Kaye D Hooper, Meenakshi Raj, Alan Coulthard, Scott R Burrows, Rajiv Khanna
Abstract
Defective control of Epstein-Barr virus (EBV) infection by cytotoxic CD8(+) T cells might predispose to multiple sclerosis (MS) by allowing EBV-infected autoreactive B cells to accumulate in the central nervous system. We have treated a patient with secondary progressive MS with in vitro-expanded autologous EBV-specific CD8(+) T cells directed against viral latent proteins. This adoptive immunotherapy had no adverse effects and the patient showed clinical improvement with reduced disease activity on magnetic resonance imaging and decreased intrathecal immunoglobulin production. This is the first report of the use of EBV-specific adoptive immunotherapy to treat MS or any other autoimmune disease.
Keywords: Adoptive immunotherapy; B cell; CD8+ T cell; Epstein–Barr virus; multiple sclerosis; treatment.
Conflict of interest statement
Conflict of interest: Michael Pender, Peter Csurhes, Corey Smith, Leonie Beagley, Kaye Hooper, Meenakshi Raj and Alan Coulthard have nothing to disclose. Scott Burrows and Rajiv Khanna hold a patent on the EBV epitopes included in the AdE1-LMPpoly construct.
© The Author(s) 2014.
Figures
References
- Ascherio A, Munger KL. Epstein-Barr virus infection and multiple sclerosis: A review. J Neuroimmune Pharmacol 2010; 5: 271–277.
- Pender MP. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 2011; 17: 351–367.
- Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003; 24: 584–588.
- Pender MP, Csurhes PA, Lenarczyk A, et al. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 498–505.
- Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204: 2899–2912.
- Tzartos JS, Khan G, Vossenkamper A, et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012; 78: 15–23.
- Smith C, Tsang J, Beagley L, et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 2012; 72: 1116–1125.
- Serafini B, Severa M, Columba-Cabezas S, et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: Implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 2010; 69: 677–693.
- Pender MP, Csurhes PA, Pfluger CMM, et al. Decreased CD8+ T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes. BMC Neurology 2011; 11: 95.
- Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 1987; 163: 319–328.
Source: PubMed